BioNxt Solutions Inc. (CSE:BNXT)
Canada · Delayed Price · Currency is CAD 0.3300
-0.0300 (-8.33%)
Aug 28, 2026, 3:21 PM EST
BioNxt Solutions Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
44.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 197.59M |
| Planet 13 Holdings | 131.28M |
| Decibel Cannabis Company | 127.08M |
| 1CM Inc. | 75.45M |
| Vext Science | 71.97M |
| Rubicon Organics | 64.23M |
| LSL Pharma Group | 41.83M |
| MediPharm Labs | 41.46M |
BioNxt Solutions News
- 4 days ago - BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies - Accesswire
- 9 days ago - BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants - Accesswire
- 11 days ago - BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies - Accesswire
- 13 days ago - BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline - Accesswire
- 4 weeks ago - BioNxt Solutions Announces Option Grants - Accesswire
- 7 weeks ago - BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway - Accesswire
- 2 months ago - BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption - Accesswire
- 2 months ago - BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF - Accesswire